Global 
Australia 
België 
Deutschland 
España 
France 
Ireland 
Italia 
Luxembourg 
Nederland 
Österreich 
Portugal 
Россия 
Schweiz 
United Kingdom 
The latest from Dr. Falk Pharma
Welcome to our Newsroom, providing you with the latest news, press releases, clinical trial announcements, events, and more from Dr. Falk Pharma.
Follow us on LinkedIn!
Falk Foundation Awards
Best IBD & EOE Posters 2026
Application closes 3rd November 2025
Strategic Partnership with Allianthera (Suzhou) Biopharmaceuticals
for Novel AhR Agonist Development for the Treatment of Moderate to Severe Ulcerative Colitis
The 2025 Dr. Falk/BASL Awards are open for entries!
Rewarding team innovation & improvement in patient care within hepatology
Positive results from pivotal phase 3 trial on norucholic acid in PSC
The results of the 96-week analysis of the NUC-5 trial will be presented at 2025 EASL Congress in Amsterdam
New General Manager for Dr. Falk Pharma UK
We are pleased to announce a significant leadership change in our UK/IE affiliate. After over 20 years of dedicated service, Anthony McFadyen ("Tony") will retire as General Manager in May 2025.
Dr. Falk Ireland Nurse Recognition Award for Improvement in Patient Care 2025
Many congratulations to Sarah Gleeson, winner of the 2025 Dr Falk Ireland Nurse Recognition Award for Improvement in Patient Care
EASL 2025
Join us from 7 – 10 May 2025 at the EASL Congress 2025 in Amsterdam, the Netherlands or online.
Following the footsteps of our founder - The End
Elena looks back and summarizes her journey: it's a collection of emotional encounters, funny moments, and, most of all, it's a big THANK YOU!
Back to the Future – Unleashing the Power of Established Drugs
Lunch satellite symposium on 21.02.2025 during the Congress of ECCO in Berlin
Dr. Falk Pharma acquires Kynos Therapeutics
...adding acute pancreatitis as a therapeutic focus and further strengthening its development portfolio
Following the footsteps of our founder
Herbert Falk's granddaughter Elena decided to follow her grandpa's footsteps. Why? Find out more and follow Elena on her journey.
Dosing of the First United States Patient
...and expansion of the Phase 2b Study of Naronapride in Gastroparesis
New Addition to the Management Board
The new Technical Operations business unit will be headed up by Dr. Andreas Rascher
FDA clearance of IND application for naronapride
...to treat gastroparesis and subsequent expansion of ongoing phase 2b study to the US
Advancing the development of naronapride...
...for patients with PPI-non-responsive symptomatic GERD as the second naronapride indication